- Home
- MWA vs AKRO Comparison
MWA vs AKRO Comparison
Compare MWA & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MWA
- AKRO
- Stock Information
- Founded
- MWA 1857
- AKRO 2017
- Country
- MWA United States
- AKRO United States
- Employees
- MWA N/A
- AKRO N/A
- Industry
- MWA Metal Fabrications
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- MWA Industrials
- AKRO Health Care
- Exchange
- MWA Nasdaq
- AKRO Nasdaq
- Market Cap
- MWA 3.9B
- AKRO 3.6B
- IPO Year
- MWA 2006
- AKRO 2019
- Fundamental
- Price
- MWA $25.33
- AKRO $42.18
- Analyst Decision
- MWA Hold
- AKRO Strong Buy
- Analyst Count
- MWA 3
- AKRO 8
- Target Price
- MWA $28.33
- AKRO $80.38
- AVG Volume (30 Days)
- MWA 979.2K
- AKRO 915.6K
- Earning Date
- MWA 11-05-2025
- AKRO 11-07-2025
- Dividend Yield
- MWA 1.05%
- AKRO N/A
- EPS Growth
- MWA 19.26
- AKRO N/A
- EPS
- MWA 0.94
- AKRO N/A
- Revenue
- MWA $1,397,100,000.00
- AKRO N/A
- Revenue This Year
- MWA $8.16
- AKRO N/A
- Revenue Next Year
- MWA $4.50
- AKRO N/A
- P/E Ratio
- MWA $27.11
- AKRO N/A
- Revenue Growth
- MWA 10.19
- AKRO N/A
- 52 Week Low
- MWA $20.49
- AKRO $21.34
- 52 Week High
- MWA $28.58
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- MWA 45.51
- AKRO 33.17
- Support Level
- MWA $24.97
- AKRO $41.77
- Resistance Level
- MWA $25.56
- AKRO $45.44
- Average True Range (ATR)
- MWA 0.71
- AKRO 1.77
- MACD
- MWA -0.17
- AKRO -0.22
- Stochastic Oscillator
- MWA 30.85
- AKRO 5.66
About MWA MUELLER WATER PRODUCTS
Mueller Water Products Inc is a U.S.-based company that manufactures and sells products and services used in the transmission, distribution, and measurement of water. The company operates in two segments Water Flow Solutions and Water Management Solutions. The Water Flow Solutions segment, which derives maximum revenue for the company, includes products like iron gate valves, specialty valves, and service brass products. Water Management Solutions' portfolio includes fire hydrants, repair and installation, natural gas, metering, leak detection, and pressure management and control products and solutions. Geographically, the company derives a majority of its revenue from the United States and the rest from Canada and other international locations.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.